期刊
CLINICAL OPHTHALMOLOGY
卷 11, 期 -, 页码 1583-1600出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OPTH.S135316
关键词
glaucoma; micro-invasive glaucoma surgery; MIGS; iStent; iStent inject; CyPass; Hydrus; XEN
资金
- Glaukos Inc., San Clemente, USA
Over the last decade several novel surgical treatment options and devices for glaucoma have been developed. All these developments aim to cause as little trauma as possible to the eye, to safely, effectively, and sustainably reduce intraocular pressure (IOP), to produce reproducible results, and to be easy to adopt. The term micro-invasive glaucoma surgery (MIGS) was used for summarizing all these procedures. Currently MIGS is gaining more and more interest and popularity. The possible reduction of the number of glaucoma medications, the ab interno approach without damaging the conjunctival tissue, and the probably safer procedures compared to incisional surgical methods may explain the increased interest in MIGS. The use of glaucoma drainage implants for lowering IOP in difficult-to-treat patients has been established for a long time, however, a variety of new glaucoma micro-stents are being manufactured by using various materials and are available to increase aqueous outflow via different pathways. This review summarizes published results of randomized clinical studies and extensive case report series on these devices, including Schlemm's canal stents (iStent (R), iStent (R) inject, Hydrus), suprachoroidal stents (CyPass (R), iStent (R) Supra), and subconjunctival stents (XEN). The article summarizes the findings of published material on efficacy and safety for each of these approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据